Related Experiment Video
Updated: Dec 30, 2025

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
FDA Perspectives on the Regulation of Neuromodulation Devices
Timothy Marjenin1, Pamela Scott1, Anita Bajaj1
1Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, MD, USA.
Abstract:
The United States Food and Drug Administration (FDA) ensures that patients in the United States have access to safe and effective medical devices. The division of neurological and physical medicine devices reviews medical technologies that interface with the nervous system, including many neuromodulation devices. This article focuses on neuromodulation devices and addresses how to navigate the FDA's regulatory landscape to successfully bring devices to patients.
Related Concept Videos
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Neural Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

